JAMA

03/13/2026

🌎 Global cardiology societies including the American Heart Association and the European Society of Cardiology released their first joint statement urging action on environmental risk factors for disease, like air pollution, heat, and noise.

Learn more about their recommendations and why they matter:

This Medical News article discusses a new joint statement from the American College of Cardiology, the American Heart Association, the European Society of Cardiology, and the World Heart Federation addressing the role of environmental risk factors in cardiovascular disease.

03/12/2026

"I found the lump myself. Pebble-sized. Firm. Uninvited."

🖋️ In , a hematologist and endurance athlete discovers an aggressive breast , causing her to redefine endurance as embracing uncertainty and vulnerability while navigating life as both physician and patient.

https://ja.ma/46UpXt8

03/12/2026

Robert Wachter, MD, chair of the Department of Medicine at UC San Francisco, speaks with JAMA+ AI Editor in Chief Roy Perlis, MD, MSc, about his new book, “A Giant Leap.”

Their discussion addresses multiple potential impacts of in in terms of clinical practice but also training the next generation of clinicians.

03/12/2026

State-level of in Oregon in 2020 and Colorado in 2022 was associated with increased 12-month psilocybin use compared with synthetic control estimates.

The observed prevalence in Oregon was 2.1 percentage points higher than expected, representing approximately 90 000 additional individuals using psilocybin annually.

In Colorado, use rose following Oregon’s measure and increased further after decriminalization, but the difference was not statistically significant, likely due to a shorter post-policy time frame.

https://ja.ma/46WowKV

03/12/2026

💬 Editorial: In a large RCT, Sinnige et al found that automated closed-loop ventilation was not superior to protocolized conventional ventilation for ventilator-free days or overall mortality.

These findings highlight the complexities of trial design and the influence of highly optimized conventional care.

https://ja.ma/4sEDjlC

03/12/2026

RCT: Among critically ill adults receiving invasive mechanical ventilation, early use of an automated closed-loop ventilation system did not increase ventilator-free days at day 28 compared with protocolized conventional ventilation.

The ACTIVE trial studied patients in 7 ICUs across the Netherlands and Switzerland.

https://ja.ma/40s4VOT

03/11/2026

💬 Viewpoint by Victor Hassid, MD, MBA, and Haytham Kaafarani, MD, MPH: Administrative delays and access failures introduce patient safety risks but are rarely treated as safety events in health systems.

https://ja.ma/4sFjgUd

03/11/2026

is a leading cause of food worldwide and affects about 2% of people in the US.

Peanut allergy involves an immune reaction to peanuts that may cause skin, gastrointestinal, respiratory, and cardiovascular symptoms, and can cause severe reactions.

📄 This JAMA Patient Page describes the symptoms, diagnosis, and treatment of peanut allergy.

https://ja.ma/4rrdODt

03/11/2026

Allergy to peanuts affects approximately 2% of individuals in the US.

Peanut allergy typically presents in early childhood, at a median age of 14 months, and approximately 10% to 30% of individuals outgrow peanut allergy.

💡 This JAMA Insights discusses , including diagnosis, introduction of peanuts to infant diet, and options.

https://ja.ma/4lnB9Vf

03/11/2026

💬 Editorial: Robinson et al evaluated hospital adoption and pricing for oncology biosimilars, finding that declining acquisition prices benefited hospitals and insurers, but adoption remained slow and markup margins persisted.

These trends indicate that biosimilar competition in oncology has not yet delivered savings on par with generic drug markets.

https://ja.ma/4bAinXb

03/11/2026

Between 2020 and 2024, hospitals paid declining acquisition prices for bevacizumab, trastuzumab, and rituximab.

Insurers reduced reimbursement at a slower pace, enabling hospital markup margins to rise. Adoption of biosimilars increased substantially, comprising >80% of use for all 3 drugs by 2024.

These trends indicate that implicit gainsharing payment methods between hospitals and insurers have resulted in increased adoption and utilization of biosimilars and narrower price gaps from reference biologics, supporting efficiency in oncology drug spending.

https://ja.ma/40reMEJ

03/11/2026

is associated with higher risk for 12 types and accounts for approximately 10% of annual new cancer cases in the US.

📄 This Review summarizes the primary biological pathways connecting obesity and cancer development.

https://ja.ma/4s4TuJi